Study Results to be Presented at The International Conference on Clinical Trials for Alzheimer's Disease (CTAD) on December 9th
YOQNEAM, Israel, Nov. 30, 2016 /PRNewswire/ -- Neuronix Ltd. [http://www.neuronixmedical.com/] today announces positive results from its pivotal, double-blind placebo-controlled, multi-center clinical study, for the assessment of safety and efficacy of the neuroAD Therapy System, in the treatment of mild to moderate Alzheimer's disease (the "Study"). Furthermore, Neuronix announces it has filed a United States Food and Drug Administration (FDA) de-novo application seeking regulatory clearance to market its neuroAD Therapy System for treatment of Alzheimer's disease. If approved, the neuroAD Therapy System would be the first medical device ever cleared by the FDA for treatment of Alzheimer's disease.
Photo - http://photos.prnewswire.com/prnh/20161128/443192 [http://photos.prnewswire.com/prnh/20161128/443192]
The Study involved 131 patients at nine medical centers in the United States and one in Israel. The Study evaluated the safety and efficacy of the neuroAD Therapy System in comparison to placebo, following six weeks of treatment and six weeks of follow-up, using the cognitive and behavioral standard scales for the evaluation of patients with Alzheimer's disease. The Study's positive outcomes confirm and extend the results of former studies conducted across the world with the neuroAD Therapy System. The detailed results of the Study will be presented at The International Conference on Clinical Trials for Alzheimer's Disease [http://www.ctad-alzheimer.com/] (CTAD), by Dr. Marwan N. Sabbagh, M.D., FAAN, (Barrow Neurological Institute, Phoenix, AZ) on Friday, December 9(th) at the Marriott Marquis San Diego Marina, in the late breaking news section.
Based on the pivotal Study findings, together with the positive results of earlier studies, Neuronix filed an FDA de-novo application seeking regulatory clearance to market its neuroAD Therapy System for treatment of Alzheimer's disease. This submission follows earlier communications with the FDA, as a result of which the neuroAD Therapy System was accepted for review under the Expedited Access Pathway (EAP) program, which is reserved exclusively for medical devices that present novel and breakthrough technologies, and target an unmet medical need which is life threatening or irreversibly debilitating.
Alzheimer's disease is considered one of the greatest unmet medical needs in the world today, with only a few available drugs offering partial clinical benefit, frequently limited by side effects. The neuroAD Therapy System is a patent-protected, non-invasive medical device, uniquely combining transcranial magnetic stimulation (TMS) with cognitive training, to concurrently target brain regions affected by Alzheimer's disease. The neuroAD Therapy System can be used in conjunction with other treatments, such as drug therapies.
"After years of research and development, and completing several prior successful clinical trials, this recent pivotal multicenter study, which was carried out in some of the most prestigious Alzheimer's research centers in the world, provides additional evidence that the neuroAD Therapy System offers an important additional potential benefit to patients with Alzheimer's disease," said Eyal Baror, CEO of Neuronix. "With these positive findings, we have applied to the FDA for marketing clearance under the EAP program, and expect to have the neuroAD Therapy System cleared in 2017. This will bring new hope for the millions of Alzheimer's patients and their families who find themselves in a race against time searching for an effective treatment to manage the effects of this debilitating and incurable disease."
"After seeing the results for myself in patients who have undergone the treatment, I believe that neuroAD is the most exciting breakthrough in the field of Alzheimer's disease research in more than a decade," said Dr. Alvaro Pascual-Leone, MD, PhD, Professor of Neurology at Harvard Medical School and chief of the Division of Cognitive Neurology at Beth Israel Deaconess Medical Center. "While there is still no cure for Alzheimer's disease, neuroAD is a non-invasive option, with minimal side effects, which has the potential to help patients maintain their cognitive abilities and the independence that so many of us take for granted."
About Neuronix Ltd. and the neuroAD(TM) Therapy System:
Neuronix Ltd. [http://www.neuronixmedical.com/] Is a privately-held company, with headquarters in Yoqneam, Israel, and with subsidiaries in USA and UK. Neuronix develops, manufactures and markets novel breakthrough medical-device technologies for treatment of Alzheimer's disease.
The neuroAD Therapy System is a patent-protected, non-invasive medical device, uniquely combining transcranial magnetic stimulation (TMS) with cognitive training, to concurrently target brain regions affected by Alzheimer's disease. This dual-stimulation is designed to improve cognitive performance of patients, following an intervention protocol, which lasts for six weeks, five days per week, with one hour-long session per day.
In multiple clinical studies, performed both in the USA and in other centers around the globe, the neuroAD(TM) Therapy System was repeatedly shown to be safe and effective in improving the cognitive performance and day-to-day activities of mild to moderate Alzheimer's disease patients, as compared with placebo.
The neuroAD(TM) Therapy System is approved for use in Europe (CE Marked 0482), as well as in other territories. It is commercially available in leading Alzheimer's centers in Europe and Asia.
In the United States, the neuroAD(TM) Therapy System is an experimental device and is not available for sale.
CONTACT: Media Contact: Sharp Communications, Inc., Jaret Posmentier,(212) 829-0002 x123
Web site: http://www.neuronixmedical.com/